Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canadian company, which develops barium, iodine and carbon active pharmaceutical ingredients. The Company is focused on producing its own barium, iodine and fullerene minerals. The Company, through its subsidiaries, Voyageur Industrial Minerals Ltd. and Voyageur Minerals Inc., is engaged in acquiring, exploring and developing raw materials for pharmaceutical... see more

TSXV:VM - Post Discussion

Voyageur Pharmaceuticals Ltd > Will VM increase PP again?
View:
Post by postie1 on Jan 16, 2023 3:28pm

Will VM increase PP again?

Based on the first substancial increase  and there still being a few days left, I wonder if the size will overshoot the target again, It does say in the release VM can increase the size of the PP. Plus they seem to be intent to reward the small guy as they are willing to help to make things happen. The math is just too good not to do what it takes to help yourself if you are eligible. Not too often you can turn X into X+ plus the warrants.
Comment by WarrantOfficer on Jan 16, 2023 4:27pm
I have pondered the timing of the PP.. With institutional financing news for 50M within a couple of months, why dilute the company 30%?
Comment by biggdogg on Jan 16, 2023 4:56pm
They have bills to pay, they are actively still running batch testing for FDA and now they are trying to begin sales. Sales requires marketing and a sales team. They need to buy bottles and ingredients, pay manufacturing costs. They probably needed to raised $5M not $1.5M, dilution is holding them back, they need some news to get the stock moving. Remeber, there are only 3 guys working in Voy with ...more  
Comment by postie1 on Jan 16, 2023 5:06pm
Myself, I am looking at it as a reward for smaller investors to reap the benefits as many have been buying and holding  VM but never able to get in on the warrants. The warrants while they may never be exercised ay least give people a chance to get ahead.  I think they may have been caught off guard at how many people really believe in this company and that there are some sizeable ...more  
Comment by whitenorth72 on Jan 16, 2023 7:05pm
I see the management as a shareholder that has vested interest in keeping the dilution to a minimum. Like Bigdawg said, they have bills to pay so it's inevitable that moves have to be made to keep this project in motion. Keeping a healthy float looks way better when shopping for debt financing. I will be sticking around for that first dividend and that's when I know we made it.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1